View Exam | PowerPak

1. NH is a 62-year-old male with history of hypertension and congestive heart failure. He is currently taking lisinopril, carvedilol, furosemide, and ibuprofen. He presents to the hospital with dyspnea and nausea. His laboratory values are checked, and his potassium level is noted to be 5.9 mEq/L. Which of NH's medications is LEAST likely to have contributed to his hyperkalemia?

A. Lisinopril B. Carvedilol C. Furosemide D. Ibuprofen

2. Which of the following statements regarding patiromer sorbitex calcium and sodium zirconium cyclosilicate is TRUE?

A. Neither patiromer sorbitex calcium nor sodium zirconium cyclosilicate have any significant drug-drug interactions. B. Both patiromer sorbitex calcium and sodium zirconium cyclosilicate may allow patients to remain on renin-angiotensin-aldosterone system-inhibiting therapy. C. Both patiromer sorbitex calcium and sodium zirconium cyclosilicate have shown efficacy in patients with acute hyperkalemia but not with chronic hyperkalemia. D. Neither patiromer sorbitex calcium nor sodium zirconium cyclosilicate have been shown to be effective in treating patients with chronic kidney disease.

3. Which of the following is a potential manifestation of hyperkalemia?

A. Depression B. Muscle weakness C. Hypocalcemia D. Urticaria

4. After participating in this activity, how often do you NOW INTEND to use assessment/monitoring strategies to prevent the recurrence of hyperkalemia in your at-risk patients?

A. Rarely B. Sometimes C. Often D. Always

5. After participating in this activity, how confident are you NOW in your ability to make appropriate treatment recommendations for your patients with hyperkalemia based on their specific needs?

A. Not confident B. Somewhat confident C. Moderately confident D. Very confident

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

2. Which of the following statements regarding patiromer sorbitex calcium and sodium zirconium cyclosilicate is TRUE?

3. Which of the following is a potential manifestation of hyperkalemia?

4. After participating in this activity, how often do you NOW INTEND to use assessment/monitoring strategies to prevent the recurrence of hyperkalemia in your at-risk patients?

5. After participating in this activity, how confident are you NOW in your ability to make appropriate treatment recommendations for your patients with hyperkalemia based on their specific needs?

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

2. Which of the following statements regarding patiromer sorbitex calcium and sodium zirconium cyclosilicate is TRUE?

3. Which of the following is a potential manifestation of hyperkalemia?

4. After participating in this activity, how often do you NOW INTEND to use assessment/monitoring strategies to prevent the recurrence of hyperkalemia in your at-risk patients?

5. After participating in this activity, how confident are you NOW in your ability to make appropriate treatment recommendations for your patients with hyperkalemia based on their specific needs?

« Return to Activity

Customers who Purchased
this Activity also Purchased